HYDROSERPINE PLUS (R-H-H)

Post-LOE

hydralazine hydrochloride; hydrochlorothiazide; reserpine

Teva

ANDAORALTABLET

Approved

Sep 1975

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

HYDROSERPINE PLUS (R-H-H) (hydralazine hydrochloride; hydrochlorothiazide; reserpine) by Teva is clinical pharmacology although the precise mechanism of action of hydralazine is not fully understood, the major effects are on the cardiovascular system. Approved for hypertension. First approved in 1975.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Although the precise mechanism of action of hydralazine is not fully understood, the major effects are on the cardiovascular system. Hydralazine apparently lowers blood pressure by exerting a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle.…

Indications (1)

Worked on HYDROSERPINE PLUS (R-H-H) at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.